Xcout Intel
SOMALOGIC, INC competitors & alternatives
The 12 closest competitors and alternatives to SOMALOGIC, INC among biotechnology companies — ranked by similarity to what SOMALOGIC, INC actually does, not by market-cap band.
Subscribe to see SOMALOGIC, INC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About SOMALOGIC, INC
SomaLogic, Inc. is an active biotechnology company headquartered in Boulder, Colorado, specializing in proteomics technology and biomarker discovery.
SOMALOGIC, INC at a glance
SOMALOGIC, INC is a biotechnology company headquartered in United States. Its most recent funding round raised $103M in November 2020.
SOMALOGIC, INC funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $103M | — | |
| Series A | $212M | 2 named | |
| SEC Form D filing | $969 | — | |
| SEC Form D filing | $44.9M | — | |
| SEC Form D filing | $163M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent SOMALOGIC, INC news
Top 12 SOMALOGIC, INC competitors
Ranked by semantic similarity — how close each company is to SOMALOGIC, INC by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Olink Proteomics provides high-throughput protein biomarker analysis products, instruments, software, and analysis services for life science research and drug development. Utilizing its proprietary Proximity Extension Assay (PEA) technology and next-generation sequencing, the company serves researchers and pharmaceutical organizations focused on biomarker discovery and precision medicine.
Similar biotechnology company
Alamar Biosciences operates as a commercial-stage proteomics firm, specializing in the highly sensitive, simultaneous identification of various proteins for both scientific research and prospective medical applications. Their integrated platform brings together proprietary instruments, specialized consumables, and unique software, forming a comprehensive, end-to-end solution. This system is designed for accurately quantifying multiple proteins, particularly those present in low concentrations, across a wide array of research and potential clinical uses.
Similar biotechnology company
Impact Proteomics provides a proprietary antigen profiling and protein identification platform that analyzes patient samples to map disease-associated antigens without cloned intermediates. The company serves biotechnology and diagnostic partners by enabling target discovery, companion diagnostics development, and therapeutic selection for oncology and autoimmune diseases.
Similar biotechnology company
Adaptive Biotechnologies Corp. is a biotechnology company headquartered in Seattle, Washington, United States. The firm focuses on decoding and analyzing the human immune system to address various diseases.
Similar biotechnology company
Harmonigenic Corp. is a diagnostics and biotechnology company headquartered in Rochester, New York. The company brings radical innovation to personalized precision medicine, focusing on initial diagnostic and treatment decisions.
Biotech
OncoHost is an Israeli precision-oncology biotechnology company that develops blood-based proteomic tests and computational analytics to characterize cancer patients and predict responses to immunotherapy. Its products are intended to help oncologists personalize treatment decisions and identify mechanisms of resistance, serving cancer patients, clinicians, pharmaceutical companies, and researchers.
Biotech
ALACRiS Theranostics GmbH is a pioneering biotechnology research company based in Berlin, Germany, specializing in omics technologies and personalized medicine solutions for health.
Biotech
Metabolomic Diagnostics is a biotechnology company located in Little Island, County Cork, Ireland, focused on metabolomics research and diagnostic solutions.
Similar biotechnology company
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
Biotech
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Biotech
Sarmal, Inc. is a San Diego-based biotechnology company founded in 2003 that develops next-generation genomic sequencing platforms, whole-genome sequencing technology, and field-deployable nucleic acid diagnostics. The company focuses on innovations in advanced nucleic acid sequencing and target sequence detection.
Biotech
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of SOMALOGIC, INC and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for SOMALOGIC, INCand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →